大理大学学报 ›› 2025, Vol. 10 ›› Issue (2): 32-36.DOI: 10. 3969 / j. issn. 2096-2266. 2025. 02. 007

• 临床医学 • 上一篇    下一篇

沙库巴曲缬沙坦钠、达格列净联合非奈利酮治疗2型糖尿病肾病合并高血压的临床疗效观察

李素梅,马晓涛,许 毅*   

  1. (西双版纳傣族自治州人民医院肾内科,云南景洪 666100)
  • 收稿日期:2024-05-06 修回日期:2024-06-17 出版日期:2025-02-15 发布日期:2025-02-26
  • 通讯作者: 许毅,副主任医师,E-mail:1424932742@qq.com。
  • 作者简介:李素梅,主治医师,主要从事急慢性肾小球疾病的诊治研究。

Observation on the Clinical Efficacy of Sacubitril Valsartan Sodium, Dapagliflozin Combined with#br# Finerenone in the Treatment of Type 2 Diabetic Nephropathy Complicated with Hypertension#br#

Li Sumei, Ma Xiaotao, Xu Yi *   

  1. (Department of Nephrology, The People′s Hospital of Xishuangbanna Dai Autonomous Prefecture, Jinghong,
    Yunnan 666100, China)
  • Received:2024-05-06 Revised:2024-06-17 Online:2025-02-15 Published:2025-02-26

摘要: 目的:探析沙库巴曲缬沙坦钠、达格列净联合非奈利酮对2型糖尿病肾病合并高血压患者血糖、血压和肾功能的影
响。方法:回顾性分析西双版纳傣族自治州人民医院2023年2—12月治疗的105例并发肾病的2型糖尿病合并高血压患者
的临床资料。按照不同的治疗用药方案,将患者分为对照组和观察组。对照组予沙库巴曲缬沙坦钠联合达格列净治疗,观
察组在对照组基础上加用非奈利酮治疗,连续治疗6个月,比较2组患者治疗前后的血糖、血压、肾功能、血浆白蛋白及血钾
水平。结果:治疗6个月后,2组患者均未产生明显不良反应,2组患者血压、血糖控制较治疗前明显改善,肾功能得到明显
恢复,且观察组患者血压、肾功能、血浆白蛋白改善情况优于对照组,差异有统计学意义(P<0.05)。结论:2型糖尿病肾病合
并高血压患者在应用沙库巴曲缬沙坦钠、达格列净的基础上给予非奈利酮治疗,能有效控制患者的血糖和血压、延缓肾病
进展,对保护肾功能具有积极意义。

关键词: 沙库巴曲缬沙坦钠, 达格列净, 非奈利酮, 糖尿病肾病, 肾功能, 血钾, 血压

Abstract: Objective: To investigate the effects of sacubitril valsartan sodium, dapagliflozin combined with finerenone on blood
glucose, blood pressure and renal function in type 2 diabetic nephropathy patients combined with hypertension. Methods: The clinical
data of 105 type 2 diabetic nephropathy patients combined with hypertension treated in the People′s Hospital of Xishuangbanna Dai
Autonomous Prefecture from February to December 2023 were retrospectively analyzed. Patients were divided into a control group and
an observation group according to different treatment regimens. The control group was treated with sacubitril valsartan sodium
combined with dapagliflozin, and the observation group was treated with finerenone on the basis of the control group. After 6 months of
continuous treatment, the blood glucose, blood pressure, renal function, plasma albumin and serum potassium levels of the two groups
were compared before and after treatment. Results: After 6 months of treatment, there were no obvious adverse reactions in two groups.
The blood pressure and blood glucose control in both groups improved significantly compared with that before treatment, and renal
function was significantly restored, and the blood pressure, renal function and plasma albumin control in the observation group were
better than those in the control group, and the differences were statistically significant (P<0.05). Conclusion: Type 2 diabetic
nephropathy patients with hypertension were treated with finerenone on the basis of using sacubitril valsartan sodium and dapagliflozin,
which can effectively control the blood glucose and blood pressure of patients, delay the progress of nephrosis, and have positive
significance in protecting renal function.

Key words: sacubitril valsartan sodium, dapagliflozin, finerenone, diabetic nephropathy, renal function, serum potassium, blood
pressure

中图分类号: